Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of ART001 in transthyretin amyloid polyneuropathy
ChiCTR2400090381Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ART001 in familial amyloid polyneuropathy (FAP), sponsored by Peking Union Medical College Hospital. Primary endpoints: Hematology, Chemistry and 7 more. Started Oct 2024; status: recruiting.
02
Drugs
ART001
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on ChiCTR2400090381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090381.